Loading...

MOREPENLAB Morepen Laboratories Ltd Other Situations Announcement

Mrpn

MRPN

Morepen Laboratories Ltd

(MOREPENLAB)

2025 Announcement

Show Summary

Summary

Share Sale Agreement

New Subsidiary Formed

Subsidiary in Dubai

Shareholding Change

Management Change

New Subsidiary Dubai

Management Change

Annual Compliance Report

Loan Agreement Signed

Earnings Call Transcript

Investor Call Update

Financial Results Released

Dividend After 23 Years

Dividend Proposal

Monitoring Report

Investor Presentation

Appointment of Auditors

New Subsidiary Formed

Business Agreement Update

Investor Call Scheduled

Management Change

Multivitamin Launch

New Drug Launch

Management Change

New Subsidiary Formed

New Product Launches

Expansion Announcement

Loratadine Approval

Loratadine Approval

Stock Acquisition

Subsidiary Status Change

New Subsidiary Created

Business Transfer Agreement

Affordable Diabetes Treatment

New Subsidiary Formation

Earnings Call Transcript

Financial Results Published

Investor Call Recording

Monitoring Report Released

QIP Proceeds Update

Investor Presentation

Investor Meeting

Health Tracking App

Director Appointments

EGM Notice Dispatch

Business Spin-off

Subsidiary Incorporation

Weight Management Launch

Management Change

Gut Health Recognition

Investor Meeting

Investor Call Update

Q2 Financial Results

QIP Monitoring Report

QIP Proceeds Status

Strong Profit Growth

Investor Presentation

Investor Conference Call

Director Appointment

Management Appointment

Diabetes Awareness Campaign

Directorate Change

Annual Meeting Notice

Director Appointment

Director Appointment

Price Movement Clarification

Earnings Call Transcript

Investor Call Audio

Financial Results Published

Management Changes

Management Changes

Management Changes

Q1 FY25 Presentation

Q1 FY25 Results

Conference Call

Fund Raise Announcement

Equity Shares Allotment

QIP Committee Outcome

Financial Statement 2024

Compliance Report

Financial Results

Investors Presentation Corr...

Earnings surge in FY24

Investor Presentation

Conference Call

Change in Appointment Date

Management Change

Certificate Issued

Compliance Certificate Subm...

Corporate Presentation Shared

Management Change

Management Change

Management Change

Management Change

Management Change

Q3 FY24 EBITDA Surges

Financial Results Published

Submission of details

Earnings Presentation (Q3’ ...

Earnings Conference Call

Management Change

Change in Management

Newspaper Advertisements

Earnings Presentation

Earnings Conference Call

Management Change

Newspaper Advertisements

Financial Statements

Financial Statements

Civil Litigation

Management Changes

Publication of Results

Related Party Transactions

Financial Statements

External Links:

Data:

Morepen Laboratories has proposed a dividend of Rs. 0.20 per share after 23 years, reporting a highest PAT of Rs. 118 crore for FY25, marking a 7.4% revenue increase to Rs. 1,830 crore from Rs. 1,704 crore in FY24.

AI Assistant

Morepen Laboratories Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.